BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31916407)

  • 1. Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma.
    Cottone L; Eden N; Usher I; Lombard P; Ye H; Ligammari L; Lindsay D; Brandner S; Pižem J; Pillay N; Tirabosco R; Amary F; Flanagan AM
    J Pathol Clin Res; 2020 Apr; 6(2):113-123. PubMed ID: 31916407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.
    Lim AM; Do H; Young RJ; Wong SQ; Angel C; Collins M; Takano EA; Corry J; Wiesenfeld D; Kleid S; Sigston E; Lyons B; Fox SB; Rischin D; Dobrovic A; Solomon B
    Int J Cancer; 2014 Aug; 135(4):887-95. PubMed ID: 24436120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation.
    Hallor KH; Staaf J; Jönsson G; Heidenblad M; Vult von Steyern F; Bauer HC; Ijszenga M; Hogendoorn PC; Mandahl N; Szuhai K; Mertens F
    Br J Cancer; 2008 Jan; 98(2):434-42. PubMed ID: 18071362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent chromosomal copy number alterations in sporadic chordomas.
    Le LP; Nielsen GP; Rosenberg AE; Thomas D; Batten JM; Deshpande V; Schwab J; Duan Z; Xavier RJ; Hornicek FJ; Iafrate AJ
    PLoS One; 2011; 6(5):e18846. PubMed ID: 21602918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.
    Choy E; MacConaill LE; Cote GM; Le LP; Shen JK; Nielsen GP; Iafrate AJ; Garraway LA; Hornicek FJ; Duan Z
    PLoS One; 2014; 9(7):e101283. PubMed ID: 24983247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.
    Andujar P; Wang J; Descatha A; Galateau-Sallé F; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Renier A; Zucman-Rossi J; Pairon JC; Jaurand MC
    Lung Cancer; 2010 Jan; 67(1):23-30. PubMed ID: 19375815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
    Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
    Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
    Sommer J; Itani DM; Homlar KC; Keedy VL; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Kelley MJ; Cates JM
    J Pathol; 2010 Apr; 220(5):608-17. PubMed ID: 20140939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
    Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
    Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.
    Natrajan R; Warren W; Messahel B; Reis-Filho JS; Brundler MA; Dome JS; Grundy PE; Vujanic G; Pritchard-Jones K; Jones C
    J Clin Pathol; 2008 Jan; 61(1):95-102. PubMed ID: 17369505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.
    Mohseny AB; Tieken C; van der Velden PA; Szuhai K; de Andrea C; Hogendoorn PC; Cleton-Jansen AM
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1095-103. PubMed ID: 20737480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
    van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
    J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
    Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
    Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma.
    Guimarães AC; Lima EM; Khayat AS; Girão Faria MH; Barem Rabenhorst SH; Pitombeira MV; Assumpção PP; de Oliveira Bahia M; Lima de Lima PD; de Arruda Cardoso Smith M; Burbano RR
    Cancer Genet Cytogenet; 2007 Nov; 179(1):45-51. PubMed ID: 17981214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.